Facilities for treating multidrug-resistant tuberculosis (MDRTB) in Europe Source: International Congress 2016 – New insights into aspects of tuberculosis epidemiology Year: 2016
Prevalence of fluoroquinolon-resistance among different MDR tuberculosis cases in Ukraine Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
MDR TB treatment results of GFATM program implementation in Tomsk, Russia Source: International Congress 2015 – Management of TB: a patient focus Year: 2015
Treatment outcomes among multidrug-resistant tuberculosis (MDR-TB) cases at a referral hospital of infectious diseases in Italy Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016
Spread of tuberculosis among household contacts of multi drug resistant tuberculosis (MDRTB) patients Source: International Congress 2014 – Tuberculosis: epidemiology and public health Year: 2014
Four cases, one family: A cluster of resistant tuberculosis Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Rifampicin-resistant tuberculosis (RR-TB) in eastern Europe Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016
Implementation of rapid drug-susceptibility testing for patients at high risk of multidrug-resistant tuberculosis in Cambodia Source: Annual Congress 2013 –Diagnostic features of tuberculosis I Year: 2013
Treatment outcomes and deaths among multidrug-resistant tuberculosis (MDR-TB) patients in Gomel region, Belarus – 2009-2010 Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013
Effectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB) Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013
Study of prevalence of drug resistance in tuberculosis (TB) patients attending a tertiary care hospital at Mumbai Source: International Congress 2016 – Epidemiological insights into tuberculosis pathogenesis Year: 2016
Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016
Dynamics analysis of MBT drug resistance to antitubercolosis second-line drugs (Saratov region hospital, Russia) Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016
Active pharmacovigilance for multidrug-resistant tuberculosis patients treated with Linezolid, Belarus – 2014-2015 Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015
Frequency of risk factors for multi-drug resistant tuberculosis among the patients enrolled at multi-drug resistant clinic in a tertiary care hospital, Pakistan Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 1 Year: 2014
The global risk of dying from multidrug-resistant tuberculosis (MDR-TB) Source: International Congress 2014 – Tuberculosis epidemiology: novel features Year: 2014
Characteristics of tuberculosis (TB) in patients that died from TB in Poland Source: International Congress 2016 – Epidemiological insights into tuberculosis pathogenesis Year: 2016
Prevalence of aminoglycoside resistance among different MDR tuberculosis cases in Ukraine Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Multidrug-resistant and extensively drug resistance tuberculosis has a strong public health and economical impact in the Republic of Moldova Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection in subpopulations Year: 2013
Prevalence and trend of ofloxacin-resistance among MDR-TB including XDR-TB cases in Ukraine Source: International Congress 2015 – Epidemiology of TB: deaths, co-morbidities, migration and children Year: 2015